Hepatobiliary and gastrointestinal manifestations of acromegaly.
Acromegaly is a unique condition characterized by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) hypersecretion usually due to a pituitary adenoma. Rarely, acromegaly can result from a GH-releasing hormone carcinoid or pancreatic neoplasm which stimulates the normal pituitary to secrete GH. This review describes the interactions between acromegaly and the gastrointestinal system. In contrast to the soft tissue and skeletal changes, clinical organomegaly of the liver, kidney, and spleen is unusual in patients with acromegaly and should warrant further investigations. The prevalence of cholelithiasis is notably increased by the use of the otherwise effective GH-lowering somatostatin analog, octreotide. Patients on long-term therapy with this agent may require anticholelithogenic treatment. The frequency of malignant and premalignant polyps of the colon justify the routine screening for these lesions in newly diagnosed patients with acromegaly.
Ezzat
S
S
Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA 90048.
D000172:Acromegaly / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000209:etiology*; D002769:Cholelithiasis / Q000139:chemically induced; D003110:Colonic Neoplasms / Q000209:etiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000209:etiology*; D005770:Gastrointestinal Neoplasms / Q000209:etiology; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008107:Liver Diseases / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide